Dataset from A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 2)

A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge Study 2)

本研究为一项随机、安慰剂对照、双盲、平行组、多中心临床试验，旨在评估通过HandiHaler®吸入装置递送的噻托溴铵（tiotropium bromide，18 μg）在因急性加重住院后康复的慢性阻塞性肺疾病（COPD）受试者中的安全性与有效性，本研究代号为出院研究2（Hospital Discharge Study 2）。